Previous close | 60.00 |
Open | 60.00 |
Bid | 59.30 x 140900 |
Ask | 59.60 x 97900 |
Day's range | 59.10 - 60.40 |
52-week range | 40.70 - 71.90 |
Volume | |
Avg. volume | 82,638 |
Market cap | 1.605B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 1,480.00 |
EPS (TTM) | 0.04 |
Earnings date | 07 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 23 May 2013 |
1y target est | 99.00 |
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the regulatory review of Cevira® (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) for potential marketing authorization in China. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX, USA. The results of the BRAVO study performed within the VA healthcare system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a blue light cystoscop